An international prospective study evaluated PANXEON, a liquid biopsy that integrates CA19-9, circulating microRNAs and exosomal microRNAs into a composite score. Results indicate favorable sensitivity for stage I–II pancreatic ductal adenocarcinoma and the ability to identify high-grade dysplasia, suggesting a potential window for intervention if findings are validated.
PANXEON combines three biomarker signals (CA19-9, circulating microRNAs, exosomal microRNAs) into a machine-learning composite score to detect pancreatic disease.
The test detected high-grade dysplasia, a precursor to invasive cancer, potentially enabling intervention before invasive disease develops.
If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Save Share LinkedIn Facebook X (Twitter) Bluesky Threads Email Copy Link Key takeaways: PANXEON assesses three pancreatic cancer biomarkers and uses machine learning to calculate a composite diagnostic score. It showed sensitivity for detecting early-stage disease and high-grade dysplasia.
Ajay Goel "We are very encouraged by the early-stage performance, because that is a tremendous clinical unmet need," Goel told Healio. "The possibility of finding high-grade dysplasia is even more exciting because it would give us the opportunity to intercept the disease before invasive cancer develops. Some members of the cohort also had pancreatic cysts, chronic pancreatitis, or familial or hereditary pancreatic cancer risk.
Blood test may detect pancreatic cancer earlier Close Ask Healio AI New! Rather than thinking about early detection, we could push the limits toward prevention." 'A more reliable picture' Pancreatic cancer is among the deadliest common malignancies, largely because symptoms often do not arise until it has reached advanced stages. Approximately 13% of patients survive 5 years after diagnosis, and that rate drops to 3% for individuals with distant disease, according to American Cancer Society statistics.
THURSDAY, Sept. 17, 2026 — An experimental blood test might be able to detect pancreatic cancer at its earliest stages, potentially saving countless lives, a new study says. The test, called PANXEON, correctly identified early-stage...
An experimental blood test could help detect early pancreatic cancer and precancerous changes, guiding decisions about further testing. People at high risk of pancreatic cancer are often monitored with imaging and other tests that can be invasive, expensive, and limited in their ability to catch the disease early. An e
Learn about a new blood test that could allow physicians to detect pancreatic cancer in its earliest stages by combining multiple biomarkers.
Pancreatic cancer is typically caught in its latest stages, when it is hardest to treat
A 2026 Nature Medicine study found the PANXEON pancreatic cancer blood test detected early-stage PDAC with 87% sensitivity and a 3% The post A New Blood Test May Catch Pancreatic Cancer Before Symptoms Appear appeared first on The Hearty Soul .
Would you take a pancreatic-cancer blood test if it became available before doctors knew exactly how to interpret every positive result? Pancreatic cancer has a timing problem: It is often found only after it has become much harder to treat. That is why an experimental blood test reported in Nature Medicine is attracti
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.